EPIDIOLEX Drug Insight and Market Forecast - 2032

“EPIDIOLEX Drug Insight and Market Forecast - 2032” report provides comprehensive insights about EPIDIOLEX for Developmental and Epileptic Encephalopathy in the 7MM. A detailed picture of the EPIDIOLEX for Developmental and Epileptic Encephalopathy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the EPIDIOLEX for Developmental and Epileptic Encephalopathy. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the EPIDIOLEX market forecast, analysis for Developmental and Epileptic Encephalopathy in the 7MM, descriptive analysis such as SWOT, analysts' views, comprehensive overview of market competitors, and brief about emerging therapies in Developmental and Epileptic Encephalopathy.

Drug Summary

EPIDIOLEX (formerly GWP42003-P), also known as EPIDYOLEX in Europe, is the first prescription, plant-derived cannabis oral formulation developed by GW pharmaceuticals. It is a novel class of antiepileptic medications with a different mechanism of action. It has been approved in the US and Europe for the treatment of seizures associated with LGS or Dravet syndrome in patients 2 years of age and older. The drug is the first FDA-approved drug that contains a purified drug substance derived from marijuana, and the active ingredient is cannabidiol (CBD). Under the controlled substances act (CSA), CBD is classified as a Schedule I substance; thus, GW Pharmaceuticals conducted nonclinical and clinical studies to assess the abuse potential of CBD to support its usage. Based on these results, DAE has rescheduled the drug to enable its launch in the US.

Cannabidiol is a structurally novel anticonvulsant. Cannabidiol does not exert its anticonvulsant effects through CB1 receptors or voltage-gated sodium channels. CBD may exert a cumulative anti-convulsant effect, modulating several endogenous systems including, but not limited to, neuronal inhibition (synaptic and extrasynaptic GABA channels), modulation of intracellular calcium (TRPV, VDAC, GPR55), and possible anti-inflammatory effects (adenosine). Furthermore, CBD does not directly bind to or activate CB1 and CB2 receptors at concentrations pharmacologically relevant to its anticonvulsant effect. Additional mechanisms under exploration include adenosine modulation, glycine, GABAergic modulation, and serotonin agonist.

The company continues to evaluate EPIDIOLEX in additional rare epilepsy conditions and currently has ongoing clinical trials in tuberous sclerosis complex (TSC) and infantile spasms. The FDA has expanded the age range of patients to whom EPIDIOLEX can be prescribed to include children as young as 1 year. The clinical and cost-effectiveness was evaluated, and NICE has recommended the usage in LGS and Dravet syndrome.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the EPIDIOLEX description, mechanism of action, dosage and administration, research and development activities in Developmental and Epileptic Encephalopathy.
• Elaborated details on EPIDIOLEX regulatory milestones and other development activities have been provided in this report.
• The report also highlights the EPIDIOLEX research and development activity in Developmental and Epileptic Encephalopathy details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around EPIDIOLEX.
• The report contains forecasted sales of EPIDIOLEX for Developmental and Epileptic Encephalopathy till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Developmental and Epileptic Encephalopathy.
• The report also features the SWOT analysis with analyst views for EPIDIOLEX in Developmental and Epileptic Encephalopathy.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

EPIDIOLEX Analytical Perspective

In-depth EPIDIOLEX Market Assessment

This report provides a detailed market assessment of EPIDIOLEX in Developmental and Epileptic Encephalopathy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

EPIDIOLEX Clinical Assessment

The report provides the clinical trials information of EPIDIOLEX for Developmental and Epileptic Encephalopathy covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Developmental and Epileptic Encephalopathy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EPIDIOLEX dominance.
• Other emerging products for Developmental and Epileptic Encephalopathy are expected to give tough market competition to EPIDIOLEX and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EPIDIOLEX in Developmental and Epileptic Encephalopathy.
• Our in-depth analysis of the forecasted sales data of EPIDIOLEX from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the EPIDIOLEX in Developmental and Epileptic Encephalopathy.

 

Key Questions Answered

• What is the product type, route of administration and mechanism of action of EPIDIOLEX?
• What is the clinical trial status of the study related to EPIDIOLEX in Developmental and Epileptic Encephalopathy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EPIDIOLEX development?
• What are the key designations that have been granted to EPIDIOLEX for Developmental and Epileptic Encephalopathy?
• What is the forecasted market scenario of EPIDIOLEX for Developmental and Epileptic Encephalopathy?
• What are the forecasted sales of EPIDIOLEX in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Developmental and Epileptic Encephalopathy and how are they giving competition to EPIDIOLEX for Developmental and Epileptic Encephalopathy?
• Which are the late-stage emerging therapies under development for the treatment of Developmental and Epileptic Encephalopathy?